Evaluation of the efficacy and safety of standardized dust mite allergen specific immunotherapy to children with allergic asthma
-
摘要: 目的:评估屋尘螨变应原特异性免疫治疗(SIT)患儿过敏性哮喘的有效性和安全性。方法:选择我科尘螨过敏的哮喘患儿136例,随机分为2组,SIT组(66例):对症治疗基础上加用3年标准化屋尘螨变应原免疫治疗;对照组(70例),仅对症治疗。评价疗效指标包括:哮喘症状评分、用药评分、皮肤点刺试验、肺功能、血清特异性IgE(sIgE)和出现新的致敏原的比例。安全性评价指标包括SIT局部和(或)全身不良反应的情况。结果:SIT组患者的哮喘症状评分、用药评分、肺功能指标、屋尘螨皮肤点刺指数与ST组比较明显改善(均P<0.01)。 SIT组无新致敏原及严重不良事件发生。结论:标准化屋尘螨SIT儿童过敏性哮喘安全、有效,可以减低屋尘螨皮肤敏感性,防止出现新的致敏原。Abstract: Objective: To evaluate the efficacy and safety of mite allergen specific immunotherapy (SIT) in treating children with allergic asthma.Method: A total of 136 patients with mite allergy were recruited into the study. They were randomly divided into two groups: SIT group (n=66) and ST (symptomatic therapy) group(n=70).They were investigated of SIT with standardized allergen vaccine or no SIT only symptomatic therapy respectively. Therapeutic evaluation index includes: asthma symptoms score, drug score, skin prick test, pulmonary function, serum specificity IgE(sIgE) and the new sensitization was also assessed. Local and systemic adverse reactions were used to evaluate the clinical safety.Result: Clinical symptom scores, drug scores, Lung function, and skin test result all improved significantly after the treatment with SIT compared to ST group(P<0.01). SIT groups do not have new sensitization and no fatal systemic reactions occurred.Conclusion: The standardized dust mite allergen specific immunotherapy is efficacious and safe to Children with allergic asthma. SIT can reduce house dust mites skin sensitivity and prevent new allergen appeared.
-
Key words:
- allergic asthma /
- specific immunotherapy /
- children /
- efficacy /
- safety
-
-
[1] BOUSQUET J,KHALTAEV N,CRUZ A A,et al. Allergic rhinitis and its impact on asthma.(ARIA)2008 update[J].Allergy, 2008,63:8-160.
[2] 中华医学会儿科分会呼吸学组.儿童支气管哮喘防治常规(试行)[J].中华儿科杂志,2004,42(2):100-104.
[3] 乔兼善. 变态反应学实验技术[M]. 北京:协和医科大学出版社, 2002:107-108.
[4] 王红玉,林小平,郝创利,等.标准化屋尘螨疫苗免疫治疗对变应性支气管哮喘的疗效[J].中华结核和呼吸杂志,2006,29(10):679-679.
[5] HOGG J C, JAMES A L, PARE P D. Evidence for inflammation in asthma[J]. Am Rev Respir Dis, 1991,143:S39-S42.
[6] BOUSQUET J,HEJJAOUI A,CLAUZEL A M,et al. Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract II.Prediction of efficacy of immunotherapy[J]. J Allergy Clin Immunol,1998,82:971-977.
[7] ALVAREZ-CUESTA E,BOUSQUET J,CANONICA G W,et al.Standards for practical allergen-specific immunotherapy[J].Allergy,2006,61:1-20.
[8] PLATTS-MILS T A E,SPORIK R B,CHAPMAN M D,et al.The role of domestic allergens.The rising trends in asthma[M]//In:Chadwick D,Cardew G,eds.Chichester,UK:John Wiley and Sons,1997:173-189.
[9] CUSTOVIC A,SMITH A H,WOODCOCK A.Indoor allergens are a primary cause of asthma[J].Eur Respir J,1998,53:155-158.
[10] AKDIS C A,AKDIS M.Mechanisms of alergen-specific immunotherapy[J].J Allergy Clin Immunol,2011,127:18-27.
[11] PICHLER C E,HELBLING A,PICHLER W J.Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma:significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity[J].Allergy,2001,56:301-306.
[12] ABRAMSON M J,PUY R M,WEINER J M.Injection allergen immunotherapy for asthma[J].Cochrane Database Syst Rev,2010,8:1186-1186.
[13] AKDIS C A,BLASER K,AKDIS M.Mechanisms of allergen specific immunotherapy[J].Chem Immunol Allergy,2006,91:195-203.
[14] MIRONE C,ALBERT F,TOSI A,et al.Efficacy and safety of subcutaneous immunotherapy with a biologically standardized extract of Ambrosia artemisiifolia pollen:a double-blind,placebo-controlled study[J].Clin Exp Allergy,2004,34:1408-1414.
[15] RANK M A,OSLIE C L,KROGMAN J L,et al.Allergn immunotherapy safety:character-rizing systemic reactions and identitying risk factors[J]. Allergy Asthma Proc,2008,29:400-405.
-
计量
- 文章访问数: 39
- PDF下载数: 30
- 施引文献: 0
下载: